Replies to post #41681 on Biotech Values

[daved]

Re alxn It's puzzling. I don't know.

I'd also say the drug was sufficiently efficacious to be approved if they had lighted on the ideal protocol. I think P & G told them in advance failure to meet the primary endpoint would mean " not another penny".

Dave